{"id":113386,"date":"2010-05-24T13:06:41","date_gmt":"2010-05-24T17:06:41","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/tumor-targeted-nanoparticle-based-gene-delivery-provides-evidence-of-therapeutic-vaccination-in-patients-with-metastatic-cancer-asco-2010\/"},"modified":"2010-05-24T13:06:41","modified_gmt":"2010-05-24T17:06:41","slug":"tumor-targeted-nanoparticle-based-gene-delivery-provides-evidence-of-therapeutic-vaccination-in-patients-with-metastatic-cancer-asco-2010","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/tumor-targeted-nanoparticle-based-gene-delivery-provides-evidence-of-therapeutic-vaccination-in-patients-with-metastatic-cancer-asco-2010\/","title":{"rendered":"Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)"},"content":{"rendered":"

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n

SAN MARINO, Calif., May 24 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation (www.epeiusbiotech.com<\/a>) today announces the clinical results of the study entitled “A Phase I\/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol” at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.<\/p>\n

SUMMARY:<\/strong> Rexin-G and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal anti-cyclin G1 construct and a controllable GM-CSF expression construct, respectively. The working hypothesis underlying this two-tier complementary approach to tumor eradication and cancer vaccination is that a personalized vaccination of a patient against his or her own specific cancer can be achieved by combining (1) a targeted vector bearing a tumoricidal payload, i.e. Rexin-G, with (2) a targeted vector bearing a potent immuno-stimulatory (GM-CSF) gene, i.e. Reximmune-C. In this model, Rexin-G is first administered to control tumor growth and expose neoantigens within the tumor microenvironment, followed by defined pulses of Reximmune-C, intended to recruit the patient’s immune cells into these lesions, thereby prompting immunologic activation, recognition of tumor neoantigens, and induction of a beneficial antitumor immunity. The initial results of a Phase I\/II dose escalation study showed that, in addition to the expected tumoricidal effects of Rexin-G, histopathologic examination of biopsied tumors from patients with a diversity of cancer types revealed targeted nanoparticle delivery, GM-CSF transgene expression, and localized immune responses within the lesions. Importantly, no circulating GM-CSF protein was detected and no dose limiting toxicity was observed throughout the treatment period. Moreover, there appears to be a significant survival benefit which suggests that this two-tier approach has considerable merit as a therapeutic vaccine.<\/p>\n

About Epeius Biotechnologies:<\/strong>
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C<\/a>, and its high-performance gene delivery systems. To learn more about these agents and\/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.<\/p>\n

News issued by: Epeius Biotechnologies Corporation<\/p>\n

\"Epeius<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/10-0504-epeiusbio_72dpi.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: (5954) :: 2010-05-0524-001<\/small><\/p>\n

Original Keywords: Epeius Biotechnologies Corporation, A Phase I\/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy, The GeneVieve Protocol, ASCO Annual Meeting, privately held biopharmaceutical company dedicated to the advancement of genetic medicine, Dr Jorge G Ignacio Epeius Biotechnologies Corporation San Marino California SAN MARINO, Calif.<\/small><\/p>\n

Alternate Headline: Epeius Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer<\/small><\/p>\n

NEWS ARCHIVE NOTE:<\/strong> this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted\/moved (and redirected) into our 3.0 platform. Also note the story “reads” counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published\/issued: Mon, 24 May 2010 13:06:41 +0000<\/p>\n

<\/small><\/p>\n

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2010-05-24 13:06:41<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I\/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-113386","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":449,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/113386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=113386"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/113386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=113386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=113386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=113386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}